Stock listing
Frankfurt:7AL0 Alligator Bioscience AB Aktie
German listing (Frankfurt) of Alligator Bioscience AB · home listing Stockholm:ATORX
Follow Alligator Bioscience AB into a list and get an email when it puts out news.
Share price · FWB:7AL0
€0.0001 EUR 0.0000 (0.0%)
Close on Nov 18, 2026
- Day range
- €0.0001 – €0.0001 EURNov 18, 2026
- Market cap
- €356,810 EURAt the close on Nov 18, 2026 · price × 3.57B shares outstanding
- 52-week range
- €0.0001 – €0.0880 EURLowest and highest trades, Nov 19, 2025 – Nov 18, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:ATORX · Home | 0.0087 SEK | +0.0001 (+1.2%) | 10,154,924 | 0.0086 | 0.0091 | 0.0086 | 0.0086 | Close on Nov 18, 2026 |
| Frankfurt:7AL0 | €0.0001 EUR | 0.0000 (0.0%) | — | €0.0001 | €0.0001 | €0.0001 | €0.0001 | Close on Nov 18, 2026 |
Splits
1 split · FWB:7AL0 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-1000 | Consolidation |
- Ticker
- Frankfurt:7AL0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 13, 2026
Nomination Committee of Alligator Bioscience proposes new board and reduced fees ahead of extraordinary general meeting on 27 November 2026
Latest earnings call · Aug 26, 2026
Alligator Bioscience (Stockholm:ATORX) Q2 2026 Earnings Call
Replay and transcript
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 15 slides
Calls
Replays
Alligator Bioscience (Stockholm:ATORX) Q2 2026 Earnings Call
Wed, Aug 26, 2026 · 9:00 AM ET
Watch TranscriptAlligator Bioscience (Stockholm:ATORX) Q1 2026 Earnings Call
Tue, May 05, 2026 · 7:00 AM ET
Watch TranscriptAlligator Bioscience (Stockholm:ATORX) Q4 2025 Earnings Call
Thu, Feb 12, 2026 · 9:00 AM ET
Watch Transcript
Latest news
Alligator Bioscience publishes prospectus in connection with rights issue
Aug 31, 2026
Closed €0.053 (+39.5%) on Aug 31, 2026
Bulletin from the Extraordinary General Meeting in Alligator Bioscience AB
Aug 26, 2026
Closed €0.053 (+39.5%) on Aug 31, 2026
Financings
Rights offering of units of ordinary shares and warrants series TO 15 and TO 16
Sep 22, 2026 · US$5.97M
Closed: SEK 58.8M raised · SEK 0.04 a unit · each unit consists of two ordinary shares, one warrant series TO 15 and one warrant… · APREA Partners AB +1
Dealers: APREA Partners AB, Vator Securities AB
Buyers: Roxette Photo S.A. (part of subscription undertakings totaling SEK 2 million); Søren Bregenholt (part of subscription undertakings totaling SEK 2 million); Vator Securities AB (guarantee commitments totaling SEK 56.8 million together with Mangold); Mangold Fondkommission AB (guarantee commitments totaling SEK 56.8 million together with Vator Securities)
Insiders: Existing shareholders including CEO Søren Bregenholt have entered into subscription undertakings totaling SEK 2 million
Use of proceeds: Repayment of bridge loans of SEK 19 million
Announced Jul 23, 2026 · Update Aug 26, 2026 · Update Aug 31, 2026 · Closed Sep 22, 2026
Warrant exercise of ordinary shares via exercise of warrants series TO 14
Feb 27, 2026 · US$5.43M
Announced: about SEK 49M · SEK 0.2 a share
Use of proceeds: General corporate purposes and loan repayment
Rights offering of units, each of two ordinary shares and one warrant series TO 14
Dec 19, 2025 · US$9.81M
Update: about SEK 91M · SEK 0.4 a unit · one (1) warrant series TO 14 per unit · Vator Securities AB +1
Dealers: Vator Securities AB (lead), Setterwalls Advokatbyrå AB
Buyers: Fenja Capital (guarantee commitment of SEK 30 million); Hans-Peter Ostler, Søren Bregenholt, Johan Giléus (intend to subscribe pro rata, approximately SEK 0.7 million in total); Roxette Photo SA (Additional subscription undertaking, part of approximately SEK 5.4 million in total); Magnus Petersson (Additional subscription undertaking, part of approximately SEK 5.4 million in total); HDF Impact BV (Top guarantee commitment, part of SEK 12.5 million in total)
Insiders: Subscription undertakings from existing major shareholders and certain members of the Board of Directors and management totalling approximately SEK 6 million
Use of proceeds: Issue costs, repayment of bridge loans and repayment of part of the outstanding loan to Fenja Capital II A/S
Announced Oct 22, 2025 · Update Oct 22, 2025 · Update Oct 23, 2025 · Update Nov 25, 2025 · Update Dec 1, 2025 · Update Dec 3, 2025 · Update Dec 19, 2025
Warrant exercise of ordinary shares via exercise of warrants series TO 13
Sep 17, 2025
Closed: SEK 28.1M in the latest tranche · SEK 3.12 a share · Vator Securities
Dealers: Vator Securities
Insiders: Chairman of the Board, CEO and CFO intend to exercise all of their TO 13, totalling approximately SEK 0.2 million
Use of proceeds: Loan repayment to Fenja Capital (50% of net proceeds) and general corporate purposes, supporting mitazalimab toward Phase 3 and a partnership
Announced Aug 27, 2025 · Update Sep 8, 2025 · Closed Sep 16, 2025 · Closed Sep 17, 2025
Warrant exercise of ordinary shares (directed issue to top guarantors of warrants series TO 12)
May 26, 2025
Closed: SEK 61.5M raised · SEK 3.68 a share · Vator Securities
Dealers: Vator Securities
Buyers: Roxette Photo SA (Subscription undertaking, part of approximately SEK 16.2 million in total undertakings); Fenja Capital II A/S (1,810,425 ordinary shares for SEK 6,662,364.00); Birger Jarl 2 AB (125,209 ordinary shares for SEK 460,769.12); Consentia Group AB (125,209 ordinary shares for SEK 460,769.12); Johan Carlström (125,209 ordinary shares for SEK 460,769.12); Ghanem Chouha (75,125 ordinary shares for SEK 276,460.00); Tony Chouha (75,125 ordinary shares for SEK 276,460.00); Ulti AB (75,125 ordinary shares for SEK 276,460.00); Bohr Invest AB (75,125 ordinary shares for SEK 276,460.00); Niclas Löwgren (62,604 ordinary shares for SEK 230,382.72); Stefan Hansson (62,604 ordinary shares for SEK 230,382.72); Great Ventures & Consulting GCV AB (62,604 ordinary shares for SEK 230,382.72); Axel Lindberg (56,344 ordinary shares for SEK 207,345.92)
Insiders: The Chairman of the Board, CEO and CFO gave subscription undertakings, part of approximately SEK 16.2 million in total undertakings
Use of proceeds: General corporate purposes, developing mitazalimab toward Phase 3, securing a mitazalimab partnership, and loan repayment
Announced Apr 28, 2025 · Update May 9, 2025 · Update May 20, 2025 · Closed May 26, 2025
Decks
Investor Presentation (September 2026)
Investor deck · 15 slides · September 2026
Q2 2026 Earnings Presentation
Earnings · 28 slides · Aug 26, 2026
Q1 2026 Earnings Presentation
Earnings · 28 slides · May 5, 2026
Investor Presentation (September 2025)
Investor deck · 32 slides · September 2025
Alligator Bioscience AB on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 35 in the last 12 months · 77 in all · newest Nov 13, 2026 · oldest 2025
- Calls
- 10 calls with a replay · 10 with a transcript · latest Aug 26, 2026
- Decks
- 17 decks · latest September 2026
Where Alligator Bioscience AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:ATORX · Home listing | Stockholm | Sweden | SEK |
| LSE:0RK9 | LSE | United Kingdom | SEK |
| LS Exchange:A41BED | LS Exchange | Germany | EUR |
| Lang & Schwarz:A41BED | Lang & Schwarz | Germany | EUR |
| Aquis:ATORXS | Aquis | United Kingdom | SEK |
| Frankfurt:7AL0 · This page | Frankfurt | Germany | EUR |
| Aquis:ATORXS | Aquis | United Kingdom | SEK |
| Stuttgart:7AL0 | Stuttgart | Germany | EUR |
Log in to ask 6ix AI your own questions about Alligator Bioscience AB.